Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

Authors

Thomas F. Gajewski, University of Chicago
April KS Salama, Duke University
Donna Niedzwiecki, CALGB Statistical Center
Jeffrey Johnson, CALGB Statistical Center
Gerald Linette, Washington University School of Medicine in St. Louis
Cynthia Bucher, Moffitt Cancer Center
Michelle A. Blaskovich, Moffitt Cancer Center
Said M. Sebti, Moffitt Cancer Center
Frank Haluska, ARIAD Pharmaceuticals, Inc.
Cancer and Leukemia Group B

Journal

Journal of Translational Medicine

Publication Date

2012

Volume

10

Inclusive Pages

246

Document Type

Open Access Publication

Rights and Permissions

Gajewski et al. Journal of Translational Medicine 2012, 10:246 http://www.translational-medicine.com/content/10/1/246

Recommended Citation

Gajewski, Thomas F.; Salama, April KS; Niedzwiecki, Donna; Johnson, Jeffrey; Linette, Gerald; Bucher, Cynthia; Blaskovich, Michelle A.; Sebti, Said M.; Haluska, Frank; and Cancer and Leukemia Group B, "Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)." Journal of Translational Medicine. 10, 246. (2012).
https://digitalcommons.wustl.edu/open_access_pubs/1269